Human epidermal growth factor receptor-2 (HER2) is involved in the development of breast cancer through the PI3K/Akt/mTOR pathway [27], and the PI3K/Akt/mTOR pathway is an important pathway involved in chemoresistance and survival of triple-negative breast cancer (TNBC) [32]. Here, ERBB2 is linked to breast carcinoma.